Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · IEX Real-Time Price · USD
3.12
+0.12 (4.00%)
At close: Dec 29, 2023, 4:00 PM
3.18
+0.06 (1.92%)
After-hours: Dec 29, 2023, 4:00 PM EST
Company Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
The company is based in London, the United Kingdom.
Akari Therapeutics, Plc
| Country | United Kingdom |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ms. Rachelle Suzanne Jacques |
Contact Details
Address: 22 Boston Wharf Road, Fl 7 Boston, Massachusetts 02210 United States | |
| Phone | (646) 350-0702 |
| Website | akaritx.com |
Stock Details
| Ticker Symbol | AKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001541157 |
| CUSIP Number | 00972G108 |
| ISIN Number | US00972G2075 |
| Employer ID | 98-1034922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ray Prudo-Chlebosz M.D. | Executive Chairman |
| Dr. Torsten Hombeck | Chief Financial Officer |
| Rachelle Suzanne Jacques | President, Chief Executive Officer and Director |
| Melissa Bradford-Klug | Chief Operating Officer |
| Dr. Miles Nunn | Chief Scientific Officer |
| Dr. John F. Neylan III, M.D. | Executive Vice President and Chief Medical Officer |
| Annie Mack | Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 1, 2023 | 6-K | Report of foreign issuer |
| Nov 16, 2023 | 6-K | Report of foreign issuer |
| Oct 27, 2023 | 424B3 | Prospectus |
| Oct 26, 2023 | EFFECT | Notice of Effectiveness |
| Oct 23, 2023 | EFFECT | Notice of Effectiveness |
| Oct 23, 2023 | EFFECT | Notice of Effectiveness |
| Oct 20, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 20, 2023 | POS AM | Post-Effective amendments for registration statement |
| Oct 20, 2023 | POS AM | Post-Effective amendments for registration statement |
| Oct 20, 2023 | F-3 | Filing |